Drug updated on 7/25/2024
Dosage Form | Injection (intravenous; atoltivimab/maftivimab/odesivimab: 241.7 mg/241.7 mg/241.7 mg per 14.5 mL [16.67 mg/16.67 mg/16.67 mg per mL] in a single dose vial; atoltivimab/maftivimab/odesivimab: 483.3 mg/483.3 mg/483.3 mg per 14.5 mL [33.33 mg/33.33 mg/33.33 mg per mL] in a single-dose vial) |
Drug Class | Zaire ebolavirus glycoprotein directed human monoclonal antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb) is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
- The total number of studies reviewed was 2 from systematic reviews/meta-analyses.
- Inmazeb reduced the mortality rate by 17% in subjects with EVD when administered at a 3 ml/kg IV dose. It is preferred over other drugs like ZMapp or Ebanga due to its significant reduction in mortality and lower rate of serious adverse effects.
- In comparison to other treatments such as REGN-EB3 and mAb114 which also reduce mortality but are recommended primarily during future outbreaks, Inmazeb stands out for current use across all age groups including neonates.
- Common adverse effects associated with Inmazeb include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills. These side effects are similar across various therapeutic agents used for treating Ebola virus disease (EVD).
- Subgroup considerations highlight that while Ebanga may be an alternative choice particularly suitable for patients with cardiovascular complications due to its specific profile despite higher overall mortality rates compared to Inmazeb.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Prescribing Information. | 2022 | Regeneron Pharmaceuticals, Inc., Tarrytown, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. | 2022 | Journal of Infection and Public Health |
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. | 2022 | The Lancet, Microbe |